Lexaria Bioscience (LEXX) has released an update.
In a groundbreaking animal study, Lexaria Bioscience has reported that its DehydraTECH-liraglutide formulation has shown promising results by outperforming its semaglutide counterpart in promoting weight loss over an 8-week period. Additionally, certain DehydraTECH-CBD formulations continued to exhibit superior performance in comparison to DehydraTECH-semaglutide, marking a significant achievement in the company’s innovative drug delivery technology.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
